突变类型,正常细胞中的氨酸激酶功能和癌症中的氨酸激酶抑制剂活性
H Vanacker1,2, P A Cassier1,2, A Dufresne1,2
1Centre Léon Bérard, rue Laennec, Lyon, 69008, France.
Scientific reports
|March 4, 2026
概括
在正常细胞中受体氨酸激酶 (RTK) 的功能可以预测氨酸激酶抑制剂 (TKI) 在相应的癌症中的有效性. 这一发现有助于选择癌症,以开发新的向癌症治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 的临床活性在具有类似受体氨酸激酶 (RTK) 突变的癌症中有所不同.
- 预测TKI疗效仍然是精确瘤学的挑战.
研究的目的:
- 测试正常细胞中的RTK功能是否可以预测相应癌症中的TKI活性.
- 在固体瘤中确定TKI疗效的生物标志物.
主要方法:
- 使用公共数据库对17个实体瘤的16个RTK进行了分析.
- 在关键试验中研究了RTK改变 (误解突变,放大,转位) 作为TKI疗效的生物标志物.
主要成果:
- 在具有RTK放大功能的癌症中,TKIs显示出最小的活性.
- TKI疗效与RTK突变类型以及RTK在正常细胞中的作用相关.
- 误解突变预测了当RTK在正常细胞中至关重要时的TKI疗效;转位是组织无关的.
结论:
- 正常细胞中的RTK功能是TKI疗效的预测生物标志物.
- 突变类型和细胞环境影响TKI反应.
- 为新型向疗法开发选择癌症的指导.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors
4.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.6K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Receptor Tyrosine Kinases
20.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.1K


